PENUMBRA, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 211.1 USD | +0.44% |
|
-5.16% | -15.96% |
| Apr. 12 | Penumbra, Inc. : The underdog in healthcare |  |
| Mar. 28 | Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate | MT |
Financials (USD)
| Sales 2024 * | 1.25B | Sales 2025 * | 1.45B | Capitalization | 8.14B |
|---|---|---|---|---|---|
| Net income 2024 * | 106M | Net income 2025 * | 154M | EV / Sales 2024 * | 6.36 x |
| Net cash position 2024 * | 217M | Net cash position 2025 * | 353M | EV / Sales 2025 * | 5.37 x |
| P/E ratio 2024 * |
76.2
x | P/E ratio 2025 * |
53.9
x | Employees | 4,200 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.18% |
More Fundamentals
* Assessed data
More news
Latest transcript on Penumbra, Inc.
More recommendations
More press releases
More news
| 1 day | +0.58% | ||
| 1 week | -5.16% | ||
| Current month | -5.28% | ||
| 1 month | -9.80% | ||
| 3 months | -19.64% | ||
| 6 months | +5.65% | ||
| Current year | -15.96% |
1 week
207.04
224.30
1 month
207.04240.40
Current year
207.04277.34
1 year
180.93348.67
3 years
114.87348.67
5 years
114.87348.67
10 years
35.32348.67
| Managers | Title | Age | Since |
|---|---|---|---|
Arani Bose
FOU | Founder | 62 | 04-06-20 |
Adam Elsesser
CEO | Chief Executive Officer | 62 | 04-06-20 |
Maggie Yuen
DFI | Director of Finance/CFO | 52 | 19-12-01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Thomas Wilder
BRD | Director/Board Member | 60 | 17-01-12 |
Harpreet Grewal
BRD | Director/Board Member | 57 | 15-03-31 |
Adam Elsesser
CEO | Chief Executive Officer | 62 | 04-06-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.21% | 16 M€ | -7.08% | ||
| 1.18% | 2 M€ | -1.17% | - | |
| 0.33% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 211.1 | +0.44% | 156 478 |
| 24-04-15 | 210.2 | -3.34% | 208,831 |
| 24-04-12 | 217.4 | -2.25% | 171,287 |
| 24-04-11 | 222.5 | +0.62% | 206,905 |
| 24-04-10 | 221.1 | -0.81% | 192,515 |
Delayed Quote Nyse, April 16, 2024 at 03:53 pm EDT
More quotes
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
210.2
USD
Average target price
280.1
USD
Spread / Average Target
+33.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.96% | 8.14B | |
| +71.74% | 12.27B | |
| -3.66% | 5.37B | |
| +2.54% | 4.85B | |
| +22.66% | 4.38B | |
| -16.61% | 4.08B | |
| -39.56% | 2.29B | |
| +2.23% | 2.01B | |
| +0.48% | 1.8B | |
| -16.54% | 1.37B |
- Stock Market
- Equities
- PEN Stock
